bioAffinity Tech Appoints New Director, CEO Gets New Contract
Ticker: BIAFW · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1712762
Sentiment: neutral
Topics: executive-compensation, board-changes, employment-agreement
Related Tickers: BIAF
TL;DR
Board shakeup at BIAF: New director in, CEO's pay locked in.
AI Summary
On January 10, 2025, bioAffinity Technologies, Inc. announced changes in its board of directors and executive compensation. Specifically, the company elected Dr. Joseph M. Smith as a new director and appointed him to the Audit Committee. Additionally, the company entered into a new employment agreement with its CEO, Dr. Richard A. U. Smith, effective January 10, 2025, which includes a base salary of $350,000 and potential bonuses.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or leadership focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — The filing involves executive appointments and compensation, which can be sensitive to market perception and company performance.
Key Numbers
- $350,000 — CEO Base Salary (Effective January 10, 2025, under a new employment agreement.)
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- Dr. Joseph M. Smith (person) — Newly elected director and Audit Committee member
- Dr. Richard A. U. Smith (person) — CEO with new employment agreement
- $350,000 (dollar_amount) — CEO's new base salary
FAQ
Who was appointed as a new director for bioAffinity Technologies, Inc.?
Dr. Joseph M. Smith was elected as a new director on January 10, 2025.
What committee was Dr. Joseph M. Smith appointed to?
Dr. Joseph M. Smith was appointed to the Audit Committee.
What is the effective date of the new employment agreement for the CEO?
The new employment agreement for the CEO, Dr. Richard A. U. Smith, is effective January 10, 2025.
What is the base salary for the CEO under the new agreement?
The base salary for Dr. Richard A. U. Smith is $350,000 per year.
What other compensation is mentioned for the CEO?
The filing mentions potential bonuses based on performance targets, but specific amounts are not detailed in this section.
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-01-14 16:15:24
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
- $300,0000 — mployment agreement with the Company to $300,0000. In addition, the Amendment provides th
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex10-1.htm (EX-10.1) — 13KB
- 0001493152-25-002144.txt ( ) — 281KB
- biaf-20250110.xsd (EX-101.SCH) — 4KB
- biaf-20250110_def.xml (EX-101.DEF) — 29KB
- biaf-20250110_lab.xml (EX-101.LAB) — 36KB
- biaf-20250110_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. bioAffinity Technologies, Inc. By: /s/ Michael Edwards Michael Edwards Chief Financial Officer Dated: January 14, 2025